EXELIXIS, INC.

Listed Company

EXELCIK 0000939767NasdaqLarge AcceleratedBiological Products, (No Diagnostic Substances)DelawareFY ends Jan 1

Period

FY 2025

Revenue

$2.32B

Net Income

$782.57M

Total Assets

$2.84B

Equity

$2.16B

Shares Out

251.36M

Op. Cash Flow

$884.27M

EXEL$55.86+26.11% · past yearDBEQ Basic

Daily closing prices

Business

Exelixis is an oncology company that discovers, develops and commercializes targeted cancer medicines. The company markets four products: CABOMETYX and COMETRIQ (both cabozantinib formulations) for multiple cancer indications, COTELLIC (cobimetinib) under collaboration with Genentech for melanoma, and MINNEBRO (esaxerenone) licensed to Daiichi Sankyo for hypertension in Japan. The company operates through direct U.S. sales of CABOMETYX and COMETRIQ, supported by commercial partnerships with Ipsen (outside U.S. and Canada) and Takeda (Japan) for cabozantinib, and maintains a clinical pipeline including lead asset zanzalintinib and multiple biotherapeutics programs in development.

Summary from 10-K filed 2026-02-10

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Total revenues	2,320	2,169	1,830	1,611	1,435
Cost of goods sold	84	76	73	58	53
Research and development	825	910	1,044	892	694
Selling, general and administrative	519	492	543	460	402
Impairment of long-lived assets	0	52	0	0	—
Restructuring	21	34	0	0	—
Total operating expenses	1,448	1,564	1,659	1,410	1,148
Income from operations	872	605	171	201	287
Interest income	69	77	87	33	8
Other income (expenses), net	−198,000	−133,000	93,000	−197,000	−184,000
Income before income taxes	941	682	258	234	294
Provision for income taxes	159	160	50	52	63
Net income	783	521	208	182	231
Basic (in dollars per share)	2.88	1.8	0.65	0.57	0.73
Diluted (in dollars per share)	2.78	1.76	0.65	0.56	0.72
Basic (in shares)	272	290	318	322	315
Diluted (in shares)	282	296	321	325	322

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	482	217	263	501	647
Marketable securities	577	894	732	—	—
Trade receivables, net	287	265	237	215	283
Inventory	22	22	17	33	27
Prepaid expenses and other current assets	76	68	68	62	58
Total current assets	1,443	1,468	1,318	1,619	1,835
Non-current marketable securities	604	637	729	—	—
Property and equipment, net	99	119	129	111	104
Deferred tax assets, net	293	420	361	231	112
Goodwill	64	64	64	64	64
Right-of-use assets and other non-current assets	342	240	342	—	—
Total assets	2,844	2,948	2,942	3,071	2,616
Accounts payable	30	38	34	33	24
Accrued compensation and benefits	102	110	93	77	62
Accrued clinical trial liabilities	66	58	72	65	78
Rebates and fees due to customers	60	62	60	50	34
Accrued collaboration liabilities	23	40	28	20	87
Other current liabilities	125	95	108	79	53
Total current liabilities	406	404	394	324	338
Non-current operating lease liabilities	173	191	190	190	51
Other non-current liabilities	104	109	94	69	8
Total liabilities	683	703	678	583	406
Commitments and contingencies (Note 12)	—	—	—	—	—
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued	0	0	0	0	0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 262,483 and 281,732 at December 31, 2025 and 2024, respectively	262,000	282,000	303,000	324,000	319,000
Additional paid-in-capital	2,234	2,344	2,441	2,537	2,428
Accumulated other comprehensive income (loss)	3	−1	−4	−15	−758,000
Accumulated deficit	−77	−99	−173	−34	−217
Total stockholders equity	2,161	2,244	2,264	2,488	2,211
Total liabilities and stockholders equity	2,844	2,948	2,942	3,071	2,616

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation and amortization	29	29	26	21	14
Impairment of long-lived assets	0	64	0	0	—
Stock-based compensation	113	94	106	108	120
Non-cash lease expense	24	27	29	18	5
Deferred taxes	126	−59	−133	−60	47
Acquired in-process research and development technology	12	51	129	107	14
Other, net	−12	−14	−17	−525,000	9
Trade receivables, net	−21	−28	−23	67	−122
Inventory	12	5	−13	−12	−13
Prepaid expenses and other assets	−134	31	−30	−28	−40
Accrued collaboration liabilities	2	−149,000	1	−63	70
Accounts payable and other liabilities	−50	−22	50	23	55
Net cash provided by operating activities	884	700	333	363	401
Purchases of marketable securities	−632	−928	−902	−1,451	—
Proceeds from maturities and sales of marketable securities	1,023	877	1,038	1,065	—
Purchases of property, equipment and other, net	−8	−28	−40	−28	−54
Acquired in-process research and development technology	−31	−38	−123	−111	−10
Net cash provided by (used in) investing activities	350	−117	−27	−524	−43
Payments for repurchases of common stock	−948	−652	−550	0	0
Proceeds from issuance of common stock under the equity incentive plan and stock purchase plan	49	62	33	24	24
Taxes paid related to net share settlement of equity awards	−71	−39	−29	−23	−39
Net cash used in financing activities	−970	−629	−546	586,000	−15
Net increase (decrease) in cash and cash equivalents	265	−46	−240	−161	343
Net cash paid for income taxes	155	170	186	128	13
Right-of-use assets obtained in exchange for lease obligations	0	15	17	156	5
Impairment of right-of-use assets	0	60	0	0	—
Unpaid liabilities incurred for purchases of in-process research and development technology	0	20	7	500,000	4
Unpaid liabilities incurred for purchases of investment	22	0	0	—	0

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is EXELIXIS, INC.'s CIK number?

EXELIXIS, INC.'s SEC CIK number is 0000939767 (939767). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find EXELIXIS, INC.'s SEC filings?

All of EXELIXIS, INC.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

When did EXELIXIS, INC. last report earnings?

EXELIXIS, INC. (EXEL) most recently filed an earnings 8-K with the SEC on May 5, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0000939767-26-000058). This is EXELIXIS, INC.'s most recent earnings filing of record — not a forecast of its next earnings date.

What is EXELIXIS, INC.'s most recent earnings 8-K?

EXELIXIS, INC.'s latest earnings 8-K (Item 2.02) was filed May 5, 2026 under accession 0000939767-26-000058. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.

View EXELIXIS, INC.'s latest earnings 8-K →
Look up any company's CIK number →